<DOC>
	<DOC>NCT00657449</DOC>
	<brief_summary>The study compares valdecoxib 40 mg once daily vs. rofecoxib 50 mg one daily in treating the signs and symptoms of acute first- or second-degree ankle sprain. The study also evaluated the disability status, tolerability and safety of these treatments.</brief_summary>
	<brief_title>A Double-Blind, Double-Dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain</brief_title>
	<detailed_description>This study was terminated early on 30 September 2004 due to safety concerns around the continued usage of rofecoxib following the withdrawal of rofecoxib from worldwide markets by Merck &amp; Co Inc.</detailed_description>
	<mesh_term>Acute Pain</mesh_term>
	<mesh_term>Ankle Injuries</mesh_term>
	<mesh_term>Sprains and Strains</mesh_term>
	<mesh_term>Rofecoxib</mesh_term>
	<mesh_term>Valdecoxib</mesh_term>
	<criteria>Patients had sustained, no more than 48 hours prior to the first dose of study medication, a first or seconddegree ankle sprain of the lateral ligament, specifically: anterior talofibular ligament and/or posterior talofibular ligament and/or calcaneofibular ligament At presentation, all patients were to have Patient's Assessment of Ankle Pain Visual Analog Scale (VAS) (0100mm) of â‰¥45 mm in the orthostatic position on full weight bearing (ie, moderate to severe pain), had a minimum rating of 2 on the Patient's Global Assessment of Ankle Injury and Patient's Assessment of Normal Function/Activity Tthe investigator opinion was that each patient required, and was eligible for, therapy with an antiinflammatory agent and/or analgesics to control symptoms None reported</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>sprains and strains</keyword>
</DOC>